MBD3L1: A Non-Coding RNA Molecule Regulating Gene Expression (G85509)

Target Name: MBD3L1

NCBI ID: G85509

MBD3L1

MBD3L1: A Non-Coding RNA Molecule Regulating Gene Expression

MBD3L1, also known as MBN1, is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in various organisms, including humans. It is a member of the MBD3 family of proteins, which are known for their ability to bind to specific DNA sequences, such as methylated CpG dinucleotides.

Recent studies have identified MBD3L1 as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique mechanism of action and its potential as a therapeutic target make it an attractive candidate for further investigation.

MBD3L1 functions as a negative regulator of gene expression by binding to specific DNA sequences, usually methylated CpG dinucleotides. This interaction between MBD3L1 and DNA creates a complex that prevents the binding of other transcription factors, thereby inhibiting gene transcription.

MBD3L1 has been shown to play a role in the regulation of various biological processes, including cell growth, apoptosis, and inflammation. It has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion, as well as in the regulation of cell survival and apoptosis.

In addition to its role in gene regulation, MBD3L1 has also been shown to play a role in the regulation of protein translation. It has been shown to interact with several ribosomal proteins and to regulate the rate of protein synthesis in cells.

MBD3L1 has also been shown to have a variety of potential therapeutic applications. For example, it has been shown to be downregulated in various diseases, including cancer, and to be upregulated in neurodegenerative diseases. This suggests that it may be a useful target for therapeutic intervention.

In addition to its potential therapeutic applications, MBD3L1 is also a potential biomarker for a variety of diseases. Its expression has been shown to be downregulated in various diseases, including cancer, and to be upregulated in neurodegenerative diseases. This suggests that it may be a useful biomarker for these diseases and for tracking the effectiveness of potential therapeutic interventions.

In conclusion, MBD3L1 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression and has been shown to be involved in a variety of biological processes. Its unique mechanism of action and its potential as a drug target and biomarker make it an attractive candidate for further investigation. Further studies are needed to fully understand its role in various biological processes and its potential as a therapeutic intervention.

Protein Name: Methyl-CpG Binding Domain Protein 3 Like 1

Functions: Transcriptional repressor

The "MBD3L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBD3L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets